What Align Technology Investors Need to Know

Shares of Healthcare sector company Align Technology moved 1.4% today, and are now trading at a price of $249.38. The large-cap stock's daily volume was 50,373 compared to its average volume of 1,093,503. The S&P 500 index returned a 0.4% performance.

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. The company is based in Tempe and has 23,800 full time employees. Its market capitalization is $19,479,670,784.

9 analysts are following Align Technology and have set target prices ranging from $160 to $314 per share. On average, they have given the company a rating of buy. At today's prices, ALGN is trading 6.93% away from its average analyst target price of $233.22 per share.

Over the last year, ALGN shares have gone down by -50.6%, which represents a difference of -38.6% when compared to the S&P 500. The stock's 52 week high is $552 per share and its 52 week low is $172.05. With average free cash flows of $625,422,333.3 that have been growing at an average rate of 18.5% over the last four years, Align Technology declining stock performance may not be reflective of the quality of its underlying business.

Date Reported Cash Flow from Operations ($ MM) Capital expenditures ($ MM) Free Cash Flow ($ MM) YoY Growth (%)
2021-12-31 1,173 -401 771 52.08
2020-12-31 662 -155 507 -15.11
2019-12-31 747 -150 598 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.